Quotes from industry partners


AbbVie

“We have seen tremendous progress in the field of genetics particularly with regard to advances in sequencing and data analytic technologies. AbbVie is very pleased to be a partner in the GENE Consortium which brings together academic, government and industry expertise with a common goal of increasing our collective understanding of the genetic basis of devastating diseases like cancer. Ultimately, this increased understanding of disease pathophysiology will help us discover and develop new treatments for patients.”

Jim Sullivan, Ph.D., Vice President, Discovery, AbbVie


Alexion

“Patients with rare diseases often suffer for years without getting an accurate diagnosis, and too many rare diseases still do not have an approved treatment option, leaving these patients and families suffering and without hope. At Alexion, our focus is to research, develop and deliver therapies that will transform the lives of patients with severe and life-threatening disorders,” said Martin Mackay, Ph.D., executive vice president and global head of R&D at Alexion. “We are excited to partner with Genomics England on the 100,000 Genomes Project, and believe that collaborations like this can accelerate the understanding of the genetic basis of rare diseases and ultimately lead to both improved diagnostics and treatments for patients and their families.”

Martin Mackay, the head of Alexion R&D


AstraZeneca

“We’re excited to be involved in what is the largest genomics collaboration in the world. Our commitment to the 100,000 Genomes Project gives us the opportunity to work side by side with leading scientists from different disciplines to better understand how complex data coming out of the project can be converted into innovative treatments and diagnostics. We are particularly looking forward to contributing our expertise in understanding the role of biomarkers and personalised healthcare in the development of targeted medicines for patients.”

Dr. Mene Pangalos, Executive Vice President of Innovative Medicines and Early Development, AstraZeneca


Biogen

“At Biogen, we are committed to understanding the genetic basis of disease, and believe the GENE Network represents the type of collaboration – across government, academia and industry — that is essential for us to rapidly identify the genetic causes of disease and develop novel treatment strategies to improve patient care,” said Sally John, Vice President, Computational Biology and Genomics. “By joining together, and applying the strengths and insights of each partner, we are hopeful that we will create new diagnostic tools and treatments for the patients who need them.”

Sally John, Vice President, Computational Biology and Genomics, Biogen


Dimension Therapeutics

“Dimension, which is developing novel treatments for rare metabolic diseases associated with the liver, is a strong supporter and advocate for public-private partnerships that can translate meaningful insights into innovation, providing new options for patients living with cancer and rare diseases,” said Dimension Therapeutics’ CEO Annalisa Jenkins, MBBS, MRCP. “We are very pleased to join with a select group of peer companies in forming the GENE Consortium and look forward to the progress of this important effort.”

Annalisa Jenkins, MBBS, MRCP, CEO of Dimension Therapeutics


GSK

“At GSK, we’re focused on harnessing advances in science and technology in our mission to develop the most effective medicines for patients. This project with Genomics England provides us with enormous opportunity to use genetic information to understand the causes of human disease; this allows us to select better starting points for our work and we believe this could greatly improve our success rate in discovering new medicines.”

Lon Cardon, Senior Vice President, Alternative Discovery and Development, GSK R&D


Helomics

“Helomics is proud to join this impressive roster of companies to collaborate with Genomics England,” commented Neil Campbell, President and CEO of Helomics Corporation. “Collaboration among companies within the personalized oncology space is the best way to discover new information and speed the innovation of treatments for patients in need. As the only diagnostics company involved in this partnership we are excited to offer our unique perspective for interpreting the genomic data and to aid in the discovery of new cancer biomarkers that may ultimately lead to more personalized cancer treatment and improved diagnostics.”

Neil Campbell, President and CEO of Helomics


Takeda

“Takeda is excited to join Genomics England and the 100,000 Genomes Project as an industry sponsor to advance genome sequence knowledge across cancer and rare diseases”

Dr. Eric Lai, SVP, Head of Pharmacogenomics and Companion


UCB

“The recent advances in DNA sequencing has the potential to bring huge benefits to patients directly through better targeting of therapies as well as indirectly through improved disease understanding leading to novel therapies. These will bring significant advances over today’s treatments and health outcomes. The Gene consortium is a great opportunity for a public private partnership to work together to enable these advances for the benefit of patients.”

Professor Duncan McHale, Vice President and Head of Global Exploratory Development, UCB NewMedicines


Share thisShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedInEmail this to someone